Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3353-3361

  Seidman, Andrew D ^a   Hudis, Clifford A ^a   Albanell, Juan ^a   Albanel, J ^a   Tong, William ^a   Tepler, Isidore ^a   Currie, Violante ^a   Moynahan, Mary Ellen ^a   Theodoulou, Maria ^a   Gollub, Mark ^a   Baselga, José ^a   Norton, Larry ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031757277     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3353     Document Type: Article

References (37)

1. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
2. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995
3. Gianni L, Munzone E, Capri G, et al: Paclitaxel in metastatic breast cancer: A trial of two doses by 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 87:1169-1175, 1995
4. Abrams JS, Vena DA, Baltz J, et al: Paclitaxel activity in heavily pretreated breast cancer: A National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13:2056-2065, 1995
5. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
6. 2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:128, 1996 (abstr 179)
7. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
8. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
9. Fountzilas G, Athanassiades A, Giannakakis T, et al: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A:47-51, 1996
10. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
11. Lopes NM, Adams EF, Pitts TW, et al: Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
12. Jordan MA, Wendell K, Gardiner S, et al: Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 56:816-825, 1996
13. Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23, 1995 (suppl 6)
14. Seidman AD, Hochhauser D, Gollub M, et al: Ninety-six hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
15. Chang AY, Boros L, Garrow R, et al: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 22:124-127, 1995 (suppl 6)
16. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997
17. Klaassen U, Wilke H, Strumberg D, et al: Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-549, 1996
18. Gilewski T, Norton L: Cytokinetics and breast cancer chemotherapy, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 751-768
19. Vergniol JC, Bruno R, Montay G, et al: Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 582:273-278, 1992.
20. Lee C: Urinary 6β-hydroxycortisol in humans: Analysis, biological variations, and reference ranges. Clin Biochem 28:49-54, 1995
21. Freilich RJ, Seidman AD: Pruritis due to 3-hour infusion of high-dose paclitaxel, and improvement with tricyclic antidepressants. J Natl Cancer Inst 87:933-943, 1995 (correspondence)
22. Harris JW, Rahman A, Kim B-R, et al: Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035, 1994
23. Dorr RT: Pharmacology of the taxanes. Pharmacotherapy 17:96s-104s, 1997 (suppl 5)
24. Rahman A, Korzekwa KR, Grogan J, et al: Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546, 1994
25. Vici P, DiLauro L, Conti F, et al: Paclitaxel activity in anthracycline refractory breast cancer patients. Tumori 83:661-664, 1997
26. Vermorken JB, ten Bokkel Huinink WW, Mandjes IAM, et al: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: A European Cancer Center trial. Semin Oncol 22:16-22, 1995 (suppl 8)
27. Saunders DE, Lawrence WD, Christensen C, et al: Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer 70:214-220, 1997
28. Klauber N, Parangi S, Flynn E, et al: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57:81-86, 1997
29. Peretz T, Sulkes A, Chollet P, et al: A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31:575, 1995 (abstr 345)
30. Huizing MT, Keung ACF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
31. Ged C, Pouliion JM, Pichard L, et al: The increase in urinary excretion of 6-β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol 28:373-387, 1989
32. Ohtsu T, Sasaki Y, Tamura T, et al: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599-606, 1995
33. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:101a, 1998
34. Mamounas E, Brown A, Smith R, et al: Effect of Taxol duration of infusion in advanced breast cancer: Results from NSABP B-26 comparing 3- to 24-hour infusion of high-dose Taxol. Proc Am Soc Clin Oncol 17:101a, 1998
35. Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients with metastatic breast cancer. The long and short of it. Proc Am Soc Clin Oncol 17:110a, 1998
36. Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998
37. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998